Renal denervation consistently achieved greater blood pressure reductions compared to placebo, with sustained effects over several years and preserved renal function.
Does catheter-based renal denervation reduce blood pressure in patients with uncontrolled hypertension?
Renal denervation provides safe, durable, and adherence-independent blood pressure reductions in patients with uncontrolled hypertension, serving as a complementary strategy to pharmacotherapy.
Absolute Event Rate: 0% vs 0%
Renal denervation is a catheter-based therapy that interrupts renal sympathetic traffic and lowers blood pressure through durable neuromodulation. Contemporary catheter-based systems deliver energy to the periadventitial space with an acceptable safety profile. Across blinded placebo-controlled trials in off-medication and on-medication settings, renal denervation achieves greater reductions in ambulatory and office blood pressure than placebo, with a uniform 24-h effect that includes night-time and early-morning periods. Long-term follow-up data from randomized programs and large registries show sustained separation in blood pressure between renal denervation and control groups, preserved renal function, and low re-intervention rates over several years, with select cohorts approaching a decade. This review summarizes the mechanism and target anatomy of renal denervation, key features and results of placebo-controlled trials, and practical considerations for integrating the procedure with contemporary pharmacologic therapy in patients with uncontrolled hypertension.
Sato et al. (Fri,) reported a other. Renal denervation consistently achieved greater blood pressure reductions compared to placebo, with sustained effects over several years and preserved renal function.